Atossa Therapeutics Adjourns Special Stockholder Meeting to October 7, 2021 to Allow Additional Time to VoteGlobeNewsWire • 09/07/21
Atossa Therapeutics Receives Approval from the Swedish Ethics Review Authority to Initiate a Phase 2 Clinical Study of Oral Endoxifen to Reduce Mammographic Breast Density in SwedenGlobeNewsWire • 09/02/21
Atossa Therapeutics Stock Lost Its Covid Mojo, and Its Pipeline Fails To ImpressInvestorPlace • 08/31/21
Atossa Therapeutics Announces Second Quarter 2021 Financial Results - Provides Corporate Update and Information about Upcoming Stockholder MeetingGlobeNewsWire • 08/13/21
Atossa Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9-10, 2021GlobeNewsWire • 08/05/21
Physician-Scientist Steven Quay: Forensic examination of Wuhan Institute of Virology COVID-19 patient specimens from December 2019 reveals extensive laboratory contamination, including evidence of genetic manipulation of the Nipah Virus, a BSL-4 pathogen PRNewsWire • 07/26/21